Karrie and Maverick
Member Since 2010
Someone on the CHF forum for dogs posted this today. Not sure if some of you are like me and not checking the health forum. I just hang out on LL. So just in case I hope you guys don't mind me posting it here just in case. If it isn't on the health forum maybe someone can share?
Sent: Thursday, January 06, 2011 4:11 PM
Subject: FDA MedWatch - Metronidazole Tablets, 250mg: Recall - Underweight Tablets
MedWatch logo MedWatch - The FDA Safety Information and Adverse Event Reporting Program
Metronidazole Tablets, 250mg: Recall - Underweight Tablets
AUDIENCE: Pharmacy, Consumer
ISSUE: Teva Pharmaceuticals and FDA notified healthcare professionals and the public of a recall of Metronidazole Tablets USP, 250mg, lot #312566, expiration date 05/2012. This product lot is being recalled due to the presence of underweight tablets. Underweight tablets may not contain the full amount of active ingredient within a single tablet, and a consumer may not receive the prescribed dose. This may cause the infection the drug was intended to treat to worsen or recur, which could be life-threatening when treating severe infections.
BACKGROUND: Metronidazole is indicated for the treatment of symptomatic and asymptomatic trichomoniasis, and treatment of asymptomatic consorts, amebiasis and a variety of anaerobic bacterial infections. The affected Metronidazole lot is packaged in 250 count bottles and was distributed nationwide to wholesalers and retailers.
RECOMMENDATION: Consumers who have lot 312566 in their possession are instructed to cease using the product and return it to their pharmacy.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
* Complete and submit the report Online: www.fda.gov/MedWatch/report.htm
* Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Read the MedWatch safety alert, including a link to the Press Release, at:
http://www.fda.gov/Safety/MedWatch/Safe ... 239312.htm
This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
FDA HHS
Sent: Thursday, January 06, 2011 4:11 PM
Subject: FDA MedWatch - Metronidazole Tablets, 250mg: Recall - Underweight Tablets
MedWatch logo MedWatch - The FDA Safety Information and Adverse Event Reporting Program
Metronidazole Tablets, 250mg: Recall - Underweight Tablets
AUDIENCE: Pharmacy, Consumer
ISSUE: Teva Pharmaceuticals and FDA notified healthcare professionals and the public of a recall of Metronidazole Tablets USP, 250mg, lot #312566, expiration date 05/2012. This product lot is being recalled due to the presence of underweight tablets. Underweight tablets may not contain the full amount of active ingredient within a single tablet, and a consumer may not receive the prescribed dose. This may cause the infection the drug was intended to treat to worsen or recur, which could be life-threatening when treating severe infections.
BACKGROUND: Metronidazole is indicated for the treatment of symptomatic and asymptomatic trichomoniasis, and treatment of asymptomatic consorts, amebiasis and a variety of anaerobic bacterial infections. The affected Metronidazole lot is packaged in 250 count bottles and was distributed nationwide to wholesalers and retailers.
RECOMMENDATION: Consumers who have lot 312566 in their possession are instructed to cease using the product and return it to their pharmacy.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
* Complete and submit the report Online: www.fda.gov/MedWatch/report.htm
* Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Read the MedWatch safety alert, including a link to the Press Release, at:
http://www.fda.gov/Safety/MedWatch/Safe ... 239312.htm
This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
FDA HHS
